Most Frequent Side Effects
Lurbinectedin (brand name Zepzelca), used for metastatic small cell lung cancer, commonly causes myelosuppression including neutropenia (57% of patients), anemia (53%), and thrombocytopenia (45%). Fatigue affects 41%, nausea 37%, decreased appetite 35%, and musculoskeletal pain 33%. These occur mostly in early treatment cycles.[1][2]
Why Myelosuppression Dominates
Bone marrow suppression leads to low blood cell counts, increasing infection, bleeding, and fatigue risks. Neutropenia often requires dose delays or reductions in over 70% of cases. Thrombocytopenia can cause bruising or bleeding.[1][3]
Gastrointestinal Issues Patients Report
Nausea and vomiting hit 37% and 21%, respectively, usually mild to moderate. Decreased appetite and constipation (20%) follow, often managed with antiemetics like ondansetron.[1][2]
Other Common Effects
- Fatigue and asthenia: 41-29%, linked to anemia.
- Elevated liver enzymes (ALT 37%, AST 29%).
- Edema (23%) and dyspnea (22%).
- Alopecia (minimal at 11%).[1]
Severe Risks and Monitoring
Serious effects include severe neutropenia (37%), febrile neutropenia (7%), and pneumonia (20%). Patients need weekly blood tests for the first two cycles, then every other cycle. G-CSF prophylaxis is recommended for neutropenia.[1][3]
How It Compares to Topotecan
Lurbinectedin shows similar myelosuppression to topotecan but lower nausea (37% vs. 64%) and fatigue (41% vs. 56%) rates in trials.[1]
[1]: Zepzelca Prescribing Information, Jazz Pharmaceuticals (FDA-approved label). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf
[2]: Trigo et al., Lancet Oncology (IMphase trial), 2020. https://pubmed.ncbi.nlm.nih.gov/32571408/
[3]: NCCN Guidelines for Small Cell Lung Cancer, Version 3.2023. https://www.nccn.org/guidelines